Sharon J Phillips1, Chelsea B Polis2, Kathryn M Curtis3. 1. Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 3. Division of Reproductive Health, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
BACKGROUND: Hormonal contraceptives are important for the health and well-being of some women living with HIV, so evaluation of evidence regarding their safety vis-à-vis HIV-related risks is important. METHODS: We updated two prior systematic reviews on the impact of hormonal contraception (HC) on HIV disease progression and female-to-male HIV transmission. RESULTS: One new study finds no increased risk for HIV disease progression or death associated with oral contraceptive use [adjusted (adj) hazard ratio (HR) 0.83, confidence interval [CI] 0.48-1.44] or injectables (adj HR 0.72, CI 0.53-0.98). Three new studies did not find significantly increased risks for measures of female-to-male HIV transmission with HC use. CONCLUSIONS: Hormonal contraceptive methods do not appear to accelerate HIV disease progression. More research is needed to clarify whether HC impacts HIV transmissibility.
BACKGROUND: Hormonal contraceptives are important for the health and well-being of some women living with HIV, so evaluation of evidence regarding their safety vis-à-vis HIV-related risks is important. METHODS: We updated two prior systematic reviews on the impact of hormonal contraception (HC) on HIV disease progression and female-to-male HIV transmission. RESULTS: One new study finds no increased risk for HIV disease progression or death associated with oral contraceptive use [adjusted (adj) hazard ratio (HR) 0.83, confidence interval [CI] 0.48-1.44] or injectables (adj HR 0.72, CI 0.53-0.98). Three new studies did not find significantly increased risks for measures of female-to-male HIV transmission with HC use. CONCLUSIONS: Hormonal contraceptive methods do not appear to accelerate HIV disease progression. More research is needed to clarify whether HC impacts HIV transmissibility.
Authors: Rena C Patel; Jared M Baeten; Renee Heffron; Ting Hong; Nicole L Davis; Kavita Nanda; Robert W Coombs; Jairam R Lingappa; Elizabeth A Bukusi; Stacey Hurst; Katherine K Thomas; Athena P Kourtis; Nelly Mugo Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731
Authors: Lisa B Haddad; Michael Monsour; Naomi K Tepper; Maura K Whiteman; Athena P Kourtis; Denise J Jamieson Journal: Am J Obstet Gynecol Date: 2017-09-01 Impact factor: 8.661
Authors: Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde Journal: Drug Saf Date: 2016-11 Impact factor: 5.606
Authors: Nancy L Hancock; Carla J Chibwesha; Marie C D Stoner; Bellington Vwalika; Sujit D Rathod; Margaret Phiri Kasaro; Elizabeth M Stringer; Jeffrey S A Stringer; Benjamin H Chi Journal: Biomed Res Int Date: 2015-12-27 Impact factor: 3.411
Authors: Michelle F Maritz; Roslyn M Ray; Alexis J Bick; Michele Tomasicchio; John G Woodland; Yashini Govender; Chanel Avenant; Janet P Hapgood Journal: PLoS One Date: 2018-04-26 Impact factor: 3.240